Meeting
2021 ASCO Annual Meeting
A comparative analysis of mortality between black and white stage III non–small cell lung cancer patients in the United States.
Authors
Elizabeth Blessing Elimimian
Cleveland Clinic Fl, Weston, FL
Elizabeth Blessing Elimimian , Rafael Arteta-Bulos , Hong Liang , Nadeem Bilani , Leah Elson , Diana Saravia , Evan W. Alley
Organizations
Cleveland Clinic Fl, Weston, FL, St Lukes Mntn States Tumor Inst, Boise, ID, Cleveland Clinic Florida, Weston, FL, University of Pennsylvania, Philadelphia, PA
Research Funding
No funding received
None
Background: Lung cancer remains the leading cause of cancer death in the United States (U.S.). For stage III non-small cell lung cancer (NSCLC), concurrent chemotherapy (CT) plus radiotherapy (RT) within 30 days (CCRT) confers a survival benefit. The proportion of Black and White NSCLC patients not receiving CCRT and their outcomes have not been explored. Methods: Stage III NSCLC in Black and White patients diagnosed between 2004 and 2015 from the U.S. NCDB were included. Those with multiple tumors and who received surgery were excluded. Six groups were analyzed: CCRT (0-30 days between CT and RT), SCRT (31-120 days between CT and RT), RT (only RT), CT (only CT), No-RT-nor-CT (didn’t receive RT nor CT), and other (uncategorized). Univariate, multivariate, and Kaplan-Meier analyses were utilized (p<0.05). Results: A total of 22,459 Black (CCRT 42.3%, SCRT 7.6%, RT 13.8%, CT 15.1%, and No-RT-nor-CT 21.2%) and 138,477 White (CCRT 43.9%, SCRT 7.0%, RT 12.7%, CT 14.9%, and No-RT-nor-CT 21.5%) stage III NSCLCs were analyzed. Male gender and White race were positive predictive factors for receiving CCRT (Table). In Black patients SCRT (HR 1.1; 95% CI 1.04-1.17), RT only (HR 1.2; 95% CI 1.81-1.99), CT only (HR 1.4; 95% CI 1.36-1.49), and No RT or CT (HR 2.6; 95% CI 2.49-2.69) was associated with decreased overall survival (OS) compared to CCRT. In White patients, SCRT (HR, 1.0; 95% CI, 0.99-1.03) did not decrease OS compared to CCRT, whereas RT only (HR 1.8; 95% CI, 1.74-1.80), CT only (HR 1.3; 95% CI, 1.29-1.34), and No RT or CT (HR 2.6; 95% CI, 2.59-2.67) were associated with decreased OS. Median OS with CCRT was 18 months for Black patients, versus 16 months for White patients (p<0.0001). Conclusions: OS was highest when CCRT was given. A lower proportion of Black cases were managed with CCRT, but Black patients benefit more from CCRT and had improved OS than White patients. Despite the known benefits of CT and RT in stage III NSCLC, the second largest management cohort received neither RT nor CT.
| Variable | Gender | Race | Age | Comorbidity | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | White | Black | < 65 | > 65 | 0 | 1 | 2 | 3 | |
| CCRT N (%) | 40753 (56.9) | 29591 (54.0) | 60841 (56.0) | 9503 (53.7) | 32493 (63.2) | 37851 (50.5) | 43470 (57.1) | 18703 (55.0) | 6103 (51.5) | 2068 (46.8) |
| Other Treatmentsa N (%) | 30863 (43.1) | 251999 (46.0) | 47858 (44.0) | 8204 (46.3) | 18945 (36.8) | 37117 (49.5) | 32649 (42.9) | 15306 (45.0) | 5753 (48.5) | 2354 (53.2) |
| Odds Ratio (95%CI) | 1.121 (1.095-1.148) | 1 | 1.158 (1.119-1.199) | 1 | 1 | 0.637 (0.617-0.658) | 1 | 0.921 (0.897-0.946) | 0.809 (0.777-0.842) | 0.661 (0.620-0.704) |
| Multivariate p-value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | ||||
aAll other treatments = SCRT + RT Only + CT Only (No-RT-nor-CT excluded).
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8552)
DOI
10.1200/JCO.2021.39.15_suppl.8552
Abstract #
8552
Poster Bd #
Online Only
Abstract Disclosures
Similar Abstracts
Abstract
2023 ASCO Quality Care Symposium
A population-based study of health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer.
First Author: Stephane Thibodeau
Abstract
2024 ASCO Annual Meeting
Clinical outcomes of maintenance durvalumab after definitive concurrent chemoradiotherapy in unresectable locally advanced stage III non-small cell lung cancer according to epidermal growth factor receptor and anaplastic lymphoma kinase status: Korean Cancer Study Group LU-22-18.
First Author: Dae-Ho Choi
Abstract
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Abstract
2020 ASCO Virtual Scientific Program
Actionable policy barriers for receiving standard of care treatment among unresected stage III non-small cell lung cancer (NSCLC) patients in the United States.
First Author: Zhiyuan Zheng